anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The energy expenditure (EE) was measured during the two periods of 30-minutes, with the 10 first minutes being discarded for analysis purposes. The other variables were recorded and monitored during the 10th and the 30th minute, in both pressure support (PS) and t-Tube (TT) modes. Patients were randomized in terms of sequence selection: PS - TT or TT - PS. In the baseline period, patients were receiving mechanical ventilation (Servo 900C and Servo 300; Siemens-Elema, Solna, Sweden), with PS ranging from 10 to 15cmH2O. During the PS mode, patients received assisted pressure ventilation of 10 cmH2O, 5 cmH2O of final positive expiratory pressure, the sensitivity of -1cmH2O and FiO2 of 0.4. During TT mode, oxygen flow was delivered in order to keep the same FiO2 that was provided in PS (0.4) as controlled by monitor screen (Datex Ohmeda S/5 - Compact Airway Module, M-COVX model, Finland). In this mode, an extensor was employed, one end of which was connected to the oxygen-enriched and the other end was secured to a 3-output ("T") connector, which was attached to the patient's ventilatory prosthesis. During the rest period (30 minutes), patients returned to the mechanical ventilation parameters utilized in the baseline period.
FIELD: nuclear engineering. SUBSTANCE: generator has column holding sorbent and radioisotope inside radiation shield and generator case, flange with seats placed above radiation shield, eluent, eluate, and bacterial air filter needles connected through flexible hoses with column, bacterial air filter, eluent tank, and switch. The latter is tour-way cock placed in seat of flange with eluent and bactericidal air filter needles communicating through flexible hoses with filter, eluent tank bottom and cover, and column inlet. Slide valve of switch has three locked positions relative to cock body: neutral, eluent tank or column, and bacterial air filter or tank cover, bacterial air filter or column. Eluent tank in the form of annular space, such as torus or double-wall cylinder is placed around radiation shield. EFFECT: improved effectiveness of scrubbing of isotope obtained from sorbent during elution process. 3 cl, 5 dwg
OBJECTIVES: Up to 85% of people living with epilepsy (PwE) reside in low-and middle-income countries. In sub-Saharan Africa, the lifetime prevalence of epilepsy is 16 per 1000 persons. In Northern rural Rwanda, a 47.7 per 1000 prevalence has been reported. As variations in prevalence across geographical areas have been observed, we studied the prevalence in Southern rural Rwanda using the same robust methodology as applied in the North.
METHODS: We conducted a three-stage, cross-sectional, door-to-door survey in two rural villages in Southern Rwanda from June 2022 to April 2023. First, trained enumerators administered the validated Limoges questionnaire for epilepsy screening. Second, neurologists examined the persons who had screened positively to confirm the epilepsy diagnosis. Third, cases with an inconclusive assessment were separately reexamined by two neurologists to reevaluate the diagnosis.
RESULTS: Enumerators screened 1745 persons (54.4% female, mean age: 24 ± 19.3 years), of whom 304 (17.4%) screened positive. Epilepsy diagnosis was confirmed in 133 (52.6% female, mean age: 30 ± 18.2 years) and active epilepsy in 130 persons. Lifetime epilepsy prevalence was 76.2 per 1000 (95% CI: 64.2-89.7‰). The highest age-specific rate occurred in the 29-49 age group. No gender-specific differences were noted. In 22.6% of the PwE, only non-convulsive seizures occurred. The treatment gap was 92.2%, including a diagnosis gap of 79.4%.
CONCLUSION: We demonstrated a very high epilepsy prevalence in Southern rural Rwanda, with over 20% of cases having only non-convulsive seizures, which are often underdiagnosed in rural Africa. In line with previous Rwandan reports, we reiterate the high burden of the disease in the country. Geographic variation in prevalence throughout Africa may result from differences in risk and aetiological factors. Case-control studies are underway to understand such differences and propose adapted health policies for epilepsy prevention.
PURPOSE:To produce the titled substance having characteristic strong fragrance of fruity or floral note, by inoculating and culturing a strain belonging to e.g. Saccharomyces genus to jasmine wax. CONSTITUTION:30-60pts.wt. of jasmine wax and 0.5-3pts.wt. of a surfactant such as sucrose are heated at 75-85 deg.C, and the dissolved mixture is poured into 70.5-87pts.wt. of refined water heated at 75-85 deg.C to obtain an emulsion (A). Separately, a medium (B) is prepared by compounding a carbon source (e.g. glucose), a nitrogen source (e.g. ammonium sulfate), inorganic salt and nutrient. 100pts.wt. of the component B is mixed with 10-20pts.wt. of the component A, if necessary sterilized at 115 deg.C for 15min, inoculated with Saccharomyces cerevisiae, Hansenula anomala, etc., and cultured aerobically at 20-30 deg.C for 10-15 days. The obtained culture product is extracted with an organic solvent such as hexane and distilled to obtain the objective fragment substance.
Methods, apparatuses, systems, and computer-readable media for identifying and executing one or more interactive condition evaluation tests and collecting and analyzing user behavior data to generate an output are provided. In some examples, user information may be received and one or more interactive condition evaluation tests may be identified. An instruction may be transmitted to a computing device of a user and executed on the computing device to enable functionality of one or more sensors that may be used in the identified tests. Upon initiating a test, data may be collected from the one or more sensors. The collected sensor data may be transmitted to the system and processed using one or more machine learning datasets. Additionally, user behavior data may be collected and processed using one or more machine learning datasets. The sensor data, the user behavior data, and other data may be used together to generate an output.
The present invention relates to field of treatment of rheumatoid arthritis. The inventors propose that PAD4, one of the enzymes which convert arginine into citrulline, is a target antigen for T cells that help the production of ACPA. They recently demonstrated that PAD immunization triggers anti-citrullinated fibrinogen antibody production in normal mice. Here, they demonstrate that the risk (OR) to develop RA associated with each of 12 HLA-DRB1 genotype correlates with the likelihood for the two HLA-DR molecules encoded by each genotype to bind at least one random peptide from PAD4, but not from citrullinated or native fibrinogen. PBLs from patients with RA, PsA and controls proliferate to PAD4 and they identify, notably, a peptide from PAD4, p8 (SEQ ID NO: 6), that stimulates T cells from RA patients and a few patients with PsA. Proliferative responses to p8 are associated with RA, shared epitope positive HLA-DR alleles and antibodies to PAD4. Thus the present invention relates to a peptide derived from the PAD4 protein and its use in the treatment and prevention of rheumatoid arthritis.
Clinically significant hyponatremia (sodium <125 mmol/L) can develop during oxcarbazepine use. In the 14 controlled epilepsy studies 2.5% of oxcarbazepine-treated patients (38/1,524) had a sodium of less than 125 mmol/L at some point during treatment, compared to no such patients assigned placebo or active control (carbamazepine and phenobarbital for adjunctive and monotherapy substitution studies, and phenytoin and valproate for the monotherapy initiation studies). Clinically significant hyponatremia generally occurred during the first 3 months of treatment with oxcarbazepine, although there were patients who first developed a serum sodium <125 mmol/L more than 1-year after initiation of therapy. Most patients who developed hyponatremia were asymptomatic but patients in the clinical trials were frequently monitored and some had their oxcarbazepine dose reduced, discontinued, or had their fluid intake restricted for hyponatremia. Whether or not these maneuvers prevented the occurrence of more severe events is unknown. Cases of symptomatic hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) have been reported during postmarketing use. In clinical trials, patients whose treatment with oxcarbazepine was discontinued due to hyponatremia generally experienced normalization of serum sodium within a few days without additional treatment.

Measurement of serum sodium levels should be considered for patients during maintenance treatment with oxcarbazepine, particularly if the patient is receiving other medications known to decrease serum sodium levels (e.g., drugs associated with inappropriate ADH secretion) or if symptoms possibly indicating hyponatremia develop (e.g., nausea, malaise, headache, lethargy, confusion, obtundation, or increase in seizure frequency or severity).
The invention relates to a method for producing molded bodies by injection molding that comprises the following steps: A) melting a mixture from a) a (meth)acrylate copolymer that is composed of 40 to 100 % by weight of radically polymerized C1- to C4 alkyl esters of the acrylic or methacrylic acid and 0 to 60 % by weight of (meth)acrylate monomers with an anionic moiety in the alkyl group. Said (meth)acrylate copolymer contains b) 0.1 to 3 % by weight of a parting compound. Optionally, c) 0 to 50 % by weight of a desiccant, d) 0 to 30 % by weight of a softener, e) 0 to 100 % by weight of additives or adjuvants, f) 0 to 100 % by weight of a pharmaceutical agent, and g) 0 to 25 % by weight of another polymer or copolymer can be contained in the mixture. The quantities indicated of components b) to g) relate to the (meth)acrylate copolymer a) and the mixture has a content in low-boiling components with a steam pressure of at least 1.9 bar at 120 degrees C or more than 0,5 % by weight before the mixture is molten. The inventive method further comprises the steps B) degassing the mixture in the thermoplastic state at temperatures of at least 120 degrees C, thereby reducing the content in low-boiling components with a steam pressure of at least 1.9 bar at 120 degrees C to not less than 0.5 % by weight, and C) injecting the molten and degassed mixture into the mold cavity of an injection-molding tool, said mold cavity having a temperature that ranges at least 10 degrees C below the glass transition temperature of the (meth)acrylate copolymer. The molten mixture is then cooled and the molded body obtained is removed from the mold.
The effect of obesity on pregnancy outcomes of patients with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology (ART) remains unclear. As such, a meta-analysis of recent studies was conducted to probe the effect of being overweight or obese on ART pregnancy outcomes in patients with PCOS. PubMed, Embase, MEDLINE, Scopus and Web of Science were searched from inception to 22 July 2023 without language restrictions. The main indicators were: live birth rate, clinical pregnancy rate, spontaneous abortion rate and multiple pregnancy rate. Ten studies were analysed, with a combined sample size of 247,845. Among patients with PCOS undergoing ART who were overweight or obese, the live birth rate, clinical pregnancy rate, implantation rate and number of retrieved oocytes were lower than in normal-weight patients with PCOS, and the spontaneous abortion rate was higher than in normal-weight patients with PCOS. Obese patients with PCOS undergoing ART had a lower multiple pregnancy rate and a lower number of mature oocytes compared with normal-weight patients with PCOS. The data showed that, among patients with PCOS, being overweight or obese has a negative effect on ART pregnancy outcomes. This meta-analysis may inform guidelines for pregnancy with ART, and encourage overweight or obese patients with PCOS to lose weight.
A prospective, multi-center, non-randomized, open label extension of the SCI EFS trial (NCT04288245) participants implanted with the investigational ReStore Device for VNS Therapy. Following the completion of Phase 2 of the SCI EFS study, participants can enroll to one of the three tracks. Under each track, participants will undergo up to 36 sessions of rehabilitative exercises self-paced by participants with targeted completion of 3 sessions per week. Evaluations will be administered at the beginning and end of each track (additional progress checks may be conducted, as required by the staff) to monitor participant progress. Upon completion of a paradigm, participants can choose to re-enroll in the same or a different track. Adverse events will be documented and assessed throughout the trial.
Methods for treating surfaces of polymeric substrates (as used in medical implants) with inert plasmas to promote the growth of bioentities (such as cells) on these surfaces is disclosed. The treated surfaces are subsequently exposed to an environment to form functionalities associated with enhanced growth of the bioentity on the surface. For example, the substrate may be exposed to the ambient environment. The bioentity may then be deposited on the modified surface. This inert plasma treatment and exposure to a suitable environment does not degrade the implants, and thus improved implants are created. Also, due to the specific functional groups at the modified surface, high cell densities are achieved.
This study is a single-center, prospective, randomized clinical trial. After obtaining ethical approval, 66 patients meeting the inclusion criteria and providing consent, who will undergo minimal invasive cardiac surgery at Ankara City Hospital Heart and Vascular Hospital Operating Room, will be included in the study. Patients will be randomized into two groups using a sealed envelope method (Group DLT: Group undergoing Single-Lung Ventilation with a Double-Lumen Tube, and Group BB: Group undergoing Single-Lung Ventilation with a bronchial blocker within a single-lumen Endotracheal Tube). Both groups will receive standard anesthesia induction and maintenance. Patients brought to the operating room without premedication will start invasive blood pressure monitoring with awake intra-arterial cannulation in addition to standard ASA monitoring.

Anesthesia induction will be performed with 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. After 3 minutes of anesthesia induction, a double-lumen tube/endotracheal tube-bronchial blocker of the appropriate size based on patients' height and gender will be placed. Tube placement will be confirmed with the assistance of a flexible bronchoscope in both groups. During anesthesia maintenance, the gas mixture of 50%/50% oxygen/air with 1-2% sevoflurane will be adjusted to maintain BIS between 40-60. During mechanical ventilation, in both groups, tidal volume of 6-8 ml/kg, respiratory rate of 10-12/min, and PEEP of 4-5 cmH2O will be set for double-lung ventilation, and for single-lung ventilation, tidal volume of 4-6 ml/kg, respiratory rate of 12-14/min, and PEEP of 4-5 cmH2O will be adjusted to maintain PIP\<25cmH2O, SpO2\>90, and PaCO2\<40 mmHg (based on ideal body weight).

Apart from the two compared airway management techniques, both groups will receive standard anesthetic care, multimodal analgesia, and cardiopulmonary bypass method. Determining the impact of these methods on pulmonary functions is crucial to avoid adding potential pulmonary complications related to the inflammatory damage caused by the cardiopulmonary bypass pump to the airway management used for single-lung ventilation. Additionally, comparing the rates of technical complications and placement times for these techniques can guide anesthesia management. Both techniques are routinely used in our clinic for the minimal invasive cardiac surgery procedure based on the preference of anesthesia providers.
This is a double-blind, placebo-controlled, randomized, dose-finding, two-stage adaptive, clinical trial study comparing allopregnanolone to placebo when administered intravenously for 5 days beginning within 8 hours after injury. Test products to be administered are low and high dose allopregnanolone (Products L and H, respectively) and placebo (Product P) intravenous solutions. The products are administered during a 4-day treatment period followed by a 1-day dose de-escalation period. Stage 1 of the study will assess safety and confirm that dosing with Products L and H achieve the target steady-state plasma concentrations set for each of these products. Dosing will be adjusted in Stage 1, if necessary. Stage 2 will initially allocate subjects equally to Products L, H and P but will then use adaptive randomization to allocate subjects between Products L and H to optimized the probability of yielding a better 3-month Glasgow Outcome Score Extended (GOS-E) score.
The present invention relates to a method for preparing compound micron pseudostellaria root soymilk tablets for reducing blood sugar and supplementing calcium. Raw material such as soymilk powder, xylitol, etc. are added into micron pseudostellaria root powder, micron ophiopogon root powder, micron spirulina powder, micron nacre powder and micron amino acid chromium through high-technology airflow superfine grinding, and processed and combined into the soymilk tablets. The soymilk tablets have the obvious function of reducing blood sugar and also have the effects of supplementing calcium, improving osteoporosis, allaying fatigue, enhancing immunity, tranquilizing, improving eyesight, etc. The soymilk tablets can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and simultaneously, the soymilk tablets have the functions of beautifying faces, keeping youthfulness, tranquilizing and reducing blood sugar because the micron nacre powder extolled as an oriental youthfulness keeping treasure and the amino acid chromium extolled as a blood sugar reducing factor are added. Therefore, the present invention is a favorable method for preparing health-care soymilk tablet products for health care and longevity, and the soymilk tablets have Chinese characteristics and are especially designed for middle-aged diabetics and old diabetics all over the world.
1,185,173. Cosmetic sticks. RICHARDSONMERRELL Ltd. 22 July, 1968 [24 April, 1967], No. 18710/67. Heading A5B. A pharmaceutical or toiletry application stick has an outer portion and a core portion made from different skin coating compositions wherein one portion is formed from a wax composition and the other portion comprises at least one active ingredient which is insoluble in the wax composition. The outer portion may contain a fragrant ingredient such as menthol or methyl salicylate and the stick may also contain an antiseptic such as hexachlorophene, an oil-soluble vitamin (e.g. vitamin A or D) or a healing agent such as allantoin. An antibacterial substance or a moisturiser such as propylene glycol may also be present.
The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
Background: Previous studies have mostly investigated the risk factors affecting the occurrence of leukoaraiosis and the risk factors affecting the severity of leukoaraiosis in patients with ischemic stroke, but there are relatively few studies on the risk factors and clinical characteristics affecting the severity of leukoaraiosis in the population with the most common type of first-episode ischemic stroke caused by intracranial atherosclerotic stenosis in China. Methods: We retrospectively studied patients with first-ever ischemic stroke due to intracranial atherosclerotic stenosis. All patients underwent diffusion weight magnetic resonance imaging and adjunctive examinations such as magnetic resonance angiography and/or computed tomography angiography and/or digital subtraction angiography. The characteristics and clinical data were also statistically analyzed. Results: Of the 504 patients enrolled, 176 (34.92%), 202 (40.08%), and 126 (25.00%) patients were in the mild, moderate, and severe groups, respectively, and the patients were older in the severe group compared with the moderate and mild groups (p < 0.05). Hypertension was more severe in the severe group compared with the severe and mild groups (p < 0.05). The time to hospital admission was shorter in the severe group compared with the moderate and mild groups (p < 0.05). The admission National Institutes of Health stroke scale was higher in the severe group than in the moderate and mild groups (p < 0.05). homocysteine, glucose, glycohemoglobin A1c, neutrophil-lymphocyte ratio, and ultrasensitive C-reactive protein to albumin ratio levels were significantly different between the three groups (p < 0.05). There was no significant correlation between the distribution of infarct foci in the anterior and posterior circulation in the three groups (p > 0.05). Conclusion: Age and homocysteine were independent risk factors for leukoaraiosis severity in patients with acute ischemic stroke, and all were positively associated with leukoaraiosis severity. Hypertension, glucose, glycohemoglobin A1c, neutrophil-lymphocyte ratio and ultrasensitive C-reactive protein to albumin ratio levels were highly significant in evaluating the prognosis of patients.
A modified human TNF.alpha. molecule capable of raising neutralizing antibodies towards wild-type human TNF.alpha. following administration of said modified TNF.alpha. molecule to a human host, wherein at least one peptide fragment of the human TNF.alpha. molecule has been substituted by at least one peptide known to contain an immunodominant T cell epitope or a truncated form of said molecule containing an immunodominant epitope and one or both flanking regions of the human TNF.alpha. molecule comprising at least one TNF.alpha. B  cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of the front .beta.-sheet, in any one of the connecting loops and/or in any one of the B', I or D strands of the back .beta.-sheet.  The modified human TNF.alpha. molecules or DNA encoding them may be formulated as vaccines against TNF.alpha. optionally with pharmaceutically acceptable adjuvants, for the prevention or treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, cancer, disseminated sclerosis, diabetes, psoriasis, osteoporosis or asthma. Human body fluids may be tested for the presence of TNF.alpha. by contact with a composition containing the modified TNF.alpha..